Objective:
To explore the role and benefits of intravitreal triamcinolone acetonide as an adjunct in vitreoretinal surgery.
Approach:
- FDA Approval: Triamcinolone acetonide injectable suspension is FDA-approved for various ocular inflammatory conditions and for visualization during vitrectomy.
- Visualization Study: An observer-masked study showed significant improvement in visualization scores after instillation of triamcinolone during vitrectomy.
- Dilution and Injection Technique: Dilution ratios of 8:1 to 12:1 are preferred for effective staining and reduced clearing time.
- Off-label Use Risks: Off-label use of preserved triamcinolone carries risks of retinal toxicity and inflammation.
- Reavailability of Triesence: Triesence was relaunched in October 2024 after a prolonged shortage, with a commitment to continued availability.
Key Findings:
- Triamcinolone enhances visualization of the vitreous during vitrectomy.
- A study indicated a mean visualization score increase from 0.5 to 3.7 after triamcinolone instillation.
- Dilution ratios of 8:1 to 12:1 are preferred for effective staining and reduced clearing time.
Interpretation:
Intravitreal triamcinolone acetonide serves as a valuable adjunct in vitreoretinal surgery, enhancing visualization and providing anti-inflammatory effects.
Limitations:
- Off-label use of preserved triamcinolone poses risks.
- Variability in non-FDA-approved formulations can lead to unpredictable outcomes.
Conclusion:
Intravitreal triamcinolone is a versatile tool in vitreoretinal surgery, with significant benefits for visualization and treatment of retinal diseases.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.